Dick 1983.

Methods	Four‐week double blind, randomised study.
Participants	Psychiatric inpatients suffering from persistent alteration of mood (depressed mood), had to be accompanied by at least 5 characteristics as mentioned in the Feighner criteria, with a minimum baseline score of 16 on the HRSD‐17. Age range: 34‐64 years old. Exclusion criteria: not stated.
Interventions	Fluvoxamine: 17 participants. Clomipramine: 15 participants. Fluvoxamine dose: 150 mg/day. Clomipramine dose: 150 mg/day. The protocol did not allow drugs other than the study medication during the study period except, if necessary, limited use of diazepam, levomepromazine (methotrimeprazine) and flunitrazepam.
Outcomes	HRSD‐17, CGI‐S, CGI‐change in condition score and a self rating scale. Total dropout, dropout due to inefficiency, dropout due to side effects, number of patients experiencing at least one side effect, side effect profile.
Funded by pharmaceutical companies	Unclear.
Fluvoxamine as an investigational or comparator drug	As an investigational drug.
Notes	Patients with depression (Feighner criteria) were included, so there might be some bipolar depression, but correct number was not reported. *The HRSD‐17 items 'genital symptoms' and 'loss of weight' were not recorded, study authors analysed left 15 items only.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomized", no further details.
Allocation concealment (selection bias)	Unclear risk	No details.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Quote: "double blind", no further details.
Incomplete outcome data (attrition bias) All outcomes	High risk	Study endpoint: 4/17 missing from fluvoxamine group (2 due to adverse effects); 4/15 missing from control group (1 due to adverse effects).
Selective reporting (reporting bias)	High risk	SDs of change score for depression were not reported.